Press release

Glytec Developing Novel Solution for Selection and Dosing of All Diabetes Medications

Sponsored by Businesswire

In spite of greater than 80 medications currently available in the U.S.
to treat diabetes, less than half of the estimated 22 million people
prescribed one or more are maintaining blood sugar levels within the
acceptable range.(1-3) The consequences not only impact
health status and quality of life, they add to the growing economic
burden of diabetes estimated in 2017 at $327 billion.(3) With
multiple patent allowances for its novel Therapy Advisor®
software-as-a-medical-device and active engagement in the FDA 510(k)
process, Glytec is poised to improve these clinical and financial
outcomes by helping providers more easily and efficaciously select and
dose all varieties of diabetes medications. No solution of like kind is
currently available, Therapy Advisor® will be the first.

This press release features multimedia. View the full release here:

Therapy Advisor® will expand the breadth of Glytec's proprietary eGlycemic Management System®, or eG ...

Therapy Advisor® will expand the breadth of Glytec’s proprietary eGlycemic Management System®, or eGMS®, a provider-directed enterprise solution for diabetes therapy management and medication optimization that serves patients across the entire continuum of care: inpatient, outpatient and virtual settings. (Graphic: Business Wire)

Therapy Advisor® will expand the breadth of Glytec’s
proprietary eGlycemic
Management System®
, or eGMS®, a
provider-directed enterprise solution for diabetes therapy management
and medication optimization that serves patients across the entire
continuum of care: inpatient, outpatient and virtual settings.

“For primary care providers, diabetes can be an extremely challenging
condition to manage. When it comes to diabetes medications, there are
literally tens of thousands of possible combinations. Choosing what’s
best for any one patient is a daunting task,” says Glytec’s chief
medical officer and diabetologist, Andrew
, MD, FACP, FACE, CDE, BC-ADM. “With Therapy Advisor®,
providers will have evidence-based guidance on which diabetes
medications are most likely to be successful for a patient, with
consideration given to relevant clinical variables and personal
preferences, including affordability. When appropriate, this can be used
for purposes of patient engagement and shared decision-making.”

The American Diabetes Association reports that an estimated $31 billion
is spent annually on insulin and other antidiabetic agents.(3)
Determining the best medication or combination of medications for a
patient with diabetes can be a months-long process of trial and error,
which on a national scale translates to billions of dollars in wasted
pharmaceutical expense. Hospitals, health systems and ACOs with
value-based and alternative reimbursement contracts will have tremendous
difficulty preserving already-slim margins if action is not taken to
reverse course. The same is true for health plans.

“Therapy Advisor® will remove the guesswork and make it much
simpler for providers,” explains Rhinehart, “and with an abundance of
evidence indicating wide variation in the choice and sequence of
diabetes medications, Therapy Advisor® will help providers
overcome therapeutic inertia and allow them to achieve the kind of
standardization and personalization that drives high-quality,
high-reliability care and better outcomes.”

Therapy Advisor® also promises to deliver a far better
patient experience. Glytec’s head of research and development, Robby
, explains: “Patients will sometimes change the frequency or
dose of their diabetes medications because they’re just not getting good
results. Or, they may not fill one or more of their scripts because the
prescribed regimen is not well-tailored to their lifestyle. We’ve
designed Therapy Advisor® to account not only for demographic
and clinical data, such as age, renal state, BMI, type of diabetes and
A1C, but also for experiential data that factors in specific patient
preferences. If a patient is on a weight loss program, for example,
Therapy Advisor® will allow for the exclusion of medications
with known side effects of weight gain. Or, if a patient has a cognitive
impairment, such as dementia, Therapy Advisor® will allow for
the exclusion of a more complex regimen that could prove confusing.
Through a process of directed questioning, Therapy Advisor®
will lead the provider to two treatment alternatives and will specify
the pros and cons of each. This will truly be a game changer.”

Therapy Advisor® incorporates guidelines authored by the
American Diabetes Association, American Association of Clinical
Endocrinologists, American College of Endocrinology, and European
Association for the Study of Diabetes.(4-6) In addition to
formulating recommendations on medication type, dose and frequency for
any one or more insulin and non-insulin options, Therapy Advisor®
will also help facilitate the intensification and deintensification of
medication regimens, including transitions on and off of insulin.

“Patients who aren’t helped by the medications they’ve been prescribed
ultimately consume more healthcare resources and incur significantly
higher healthcare costs,” Rhinehart adds. “These patients are
hospitalized more often, have more trips to emergency departments and
urgent care centers, and develop more concomitant conditions. They
deserve better. Therapy Advisor® is positioned to support our
nation’s providers in delivering safer, more efficacious diabetes care,
and the cost savings will follow.”




in America, 3rd Edition, Chapter 39: Medication Use and Self-Care
Practices in Persons with Diabetes. National Institutes of Health,
NIH Pub No. 17-1468, 2018.


G, Huynh J, Tuttle E, Yee J, Edelman S. Achievement of glycated
hemoglobin goals in the US remains unchanged through 2014.
Diabetes Ther. 2017 Aug;8(4):863-873.


Diabetes Association. Economic costs of diabetes in the U.S. in
2017. Diabetes Care. 2018 May;41(5):917-928.


Diabetes Association. Standards of Medical Care in Diabetes –
2019. Diabetes Care. 2019 Jan;42(Suppl 1)


A, et al. Consensus Statement by the American Association of
Clinical Endocrinologists and American College of Endocrinology on
the Comprehensive Type 2 Diabetes Management Algorithm – 2019
Executive Summary. Endocr Pract. 2019;25:69-100.


MJ, et al. Management of Hyperglycemia in Type 2 Diabetes, 2018. A
Consensus Report by the American Diabetes Association (ADA) and
the European Association for the Study of Diabetes (EASD).
Diabetes Care. 2018 Dec;41(12):2669-2701.

About Glytec
Founded in 2006, Glytec is the pioneer of
digital therapeutics, improving the lives of people with diabetes by
making insulin a more effective and accessible option for millions
unable to achieve their treatment goals. The company’s patented
eGlycemic Management System® is the only FDA-cleared
software-as-a-medical-device (SaMD) platform to enable the mass
personalization of insulin across the continuum of care: inpatient,
outpatient and virtual settings alike. Glytec offers several
comprehensive programs combining evidence-based decision support
technologies with expert professional services proven to aid providers
in achieving best practices and standardization while reducing
hyperglycemia, hypoglycemia, A1C, readmissions, length of stay and cost.
The company has offices in Waltham, Massachusetts and Greenville, South
Carolina. For more information visit